Family · Pharmaceutical analytical standards
Dapagliflozin
The first gliflozin (SGLT2 inhibitor) approved in Europe, in 2012, for type 2 diabetes. It removes excess glucose through the urine, independently of insulin. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards and other impurities.
Did you know?Born as a diabetes medicine, it has also shown benefits in heart failure and chronic kidney disease, even in people without diabetes.
No product matches your search.
EDQM standards 4
The official European Pharmacopoeia standards for this family.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
